Condition
Localized Gallbladder Cancer
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Terminated2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT00949949Phase 1Completed
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
NCT00023946Phase 2Terminated
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
NCT00087191Not ApplicableTerminated
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Showing all 3 trials